
|Videos|February 13, 2013
Introduction: Advances and Issues in NSCLC
Advertisement
For High-Definition, Click
In the first installment of the series, the moderator, David R. Gandara, MD, provides an overview of the topics that will be discussed by the panel, which includes: Corey J. Langer, MD, Alan B. Sandler, MD, Mark A. Socinski, MD, and Anne S. Tsao, MD.
Gandara notes that this Peer Exchange discussion will focus on a range of issues and challanges facing physicians who treat patients with lung cancer. Specifically, the panel will examine new therapies and testing for molecular abnormalities and the integration of these test results into the treatment decision making process.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































